Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer

Annals of Oncology

Volumn 27, Issue 2, 2016, Pages 262-266

  Mitsuhashi, Akira ^a   Sato, Y ^b   Kiyokawa, T ^a   Koshizaka, M ^b   Hanaoka, H ^b   Shozu, M ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Endometrial cancer; Fertility sparing treatment; Insulin resistance; Medroxyprogesterone acetate; Metformin

Indexed keywords

INSULIN; MEDROXYPROGESTERONE ACETATE; METFORMIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; ATYPICAL ENDOMETRIAL HYPERPLASIA; BODY MASS; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONCEPTION; CONSERVATIVE TREATMENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE FERTILITY; FOLLOW UP; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; METABOLIC PARAMETERS; NAUSEA; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG EFFECTS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FERTILITY; FERTILITY PRESERVATION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FERTILITY; FERTILITY PRESERVATION; HUMANS; INSULIN RESISTANCE; MEDROXYPROGESTERONE ACETATE; METFORMIN; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84961668063     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv539     Document Type: Article

References (27)

1. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-482.
2. Gallos ID, Yap J, Rajkhowa M et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2012; 207: 266.e1-266.e12.
3. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565-574.
4. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
6. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
7. Mu N, Zhu Y, Wang Y et al. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol 2012; 125: 751-757.
8. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48: R31-R43.
9. Quinn BJ, Kitagawa H, Memmott RM et al. Repositioning metformin for cancer prevention and treatment. Trend Endocrinol Metab 2013; 24: 469-480.
10. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143-156.
11. Foretz M, Hébrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355-2369.
12. Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
13. Decensi A, Puntoni M, Goodwin P et al. Metformin and cancer risk in diabetic patients:a systematic review and meta-analysis. Cancer Prev Res 2010; 3: 1451-1461.
14. Ko EM, Walter P, Jackson A et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014; 132: 438-442.
15. Nevadunsky NS, Van Arsdale A, Strickler HD et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2014; 132: 236-240.
16. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 2014; 120: 2986-2995.
17. Ushijima K, Yahata H, Yoshikawa H et al. Multicenter phase II study of fertilitysparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007; 25: 2798-2803.
18. Yamazawa K, Hirai M, Fujito A et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007; 22: 1953-1958.
19. Kim YB, Holschneider CH, Ghosh K et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997; 79: 320-327.
20. Kaku T, Yoshikawa H, Tsuda H et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women:central pathologic review and treatment outcome. Cancer Lett 2001; 167: 39-48.
21. Niwa K, Tagami K, Lian Z et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005; 112: 317-320.
22. Yahata T, Fujita K, Aoki Y et al. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 2006; 21: 1070-1075.
23. Park JY, Lee SH, Seong SJ et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013; 129: 7-11.
24. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121: 149-157.e2.
25. Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008; 358: 47-54.
26. Laskov I, Drudi L, Beauchamp MC et al. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 2014; 134: 607-614.
27. Schuler KM, Rambally BS, DiFurio MJ et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 2015; 4: 161-173.